JP2019528290A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528290A5
JP2019528290A5 JP2019510593A JP2019510593A JP2019528290A5 JP 2019528290 A5 JP2019528290 A5 JP 2019528290A5 JP 2019510593 A JP2019510593 A JP 2019510593A JP 2019510593 A JP2019510593 A JP 2019510593A JP 2019528290 A5 JP2019528290 A5 JP 2019528290A5
Authority
JP
Japan
Prior art keywords
diazaspiro
thioxo
benzamide
pyridyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019510593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528290A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/055063 external-priority patent/WO2018037342A1/en
Publication of JP2019528290A publication Critical patent/JP2019528290A/ja
Publication of JP2019528290A5 publication Critical patent/JP2019528290A5/ja
Pending legal-status Critical Current

Links

JP2019510593A 2016-08-22 2017-08-22 癌の治療のためのチオヒダントインアンドロゲン受容体アンタゴニスト Pending JP2019528290A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377932P 2016-08-22 2016-08-22
US62/377,932 2016-08-22
PCT/IB2017/055063 WO2018037342A1 (en) 2016-08-22 2017-08-22 Thiohydantoin androgen receptor antagonists for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2019528290A JP2019528290A (ja) 2019-10-10
JP2019528290A5 true JP2019528290A5 (enExample) 2020-10-01

Family

ID=60009664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019510593A Pending JP2019528290A (ja) 2016-08-22 2017-08-22 癌の治療のためのチオヒダントインアンドロゲン受容体アンタゴニスト

Country Status (12)

Country Link
US (1) US20190209539A1 (enExample)
EP (1) EP3500259A1 (enExample)
JP (1) JP2019528290A (enExample)
KR (1) KR20190040030A (enExample)
CN (1) CN109640986A (enExample)
AU (1) AU2017316756A1 (enExample)
BR (1) BR112019003406A2 (enExample)
CA (1) CA3034449A1 (enExample)
MA (1) MA45992A (enExample)
MX (1) MX2019002097A (enExample)
RU (1) RU2019108092A (enExample)
WO (1) WO2018037342A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032644B (zh) * 2017-08-07 2021-08-10 正大天晴药业集团股份有限公司 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
BR112021015122A2 (pt) 2019-02-01 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Cristal de composto de diariltio-hidantoína
CN115403624B (zh) * 2022-09-30 2024-08-27 上海应用技术大学 一种二芳基硫代乙内酰脲化合物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028869B1 (ru) * 2010-02-16 2018-01-31 Арагон Фармасьютикалс, Инк. Модуляторы рецептора андрогенов и их применение
EP2911666B1 (en) * 2012-10-26 2022-08-24 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor

Similar Documents

Publication Publication Date Title
JP2019528290A5 (enExample)
Gooderham et al. Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast
Cui et al. Efficacy and safety of long‐term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction
JP2019503365A5 (enExample)
JP2010509369A5 (enExample)
JP2013535437A5 (enExample)
RU2017114346A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
JP2015500223A5 (enExample)
JP2015212268A5 (enExample)
JP2014240408A5 (enExample)
JP2017504611A5 (enExample)
JP2018537507A5 (enExample)
JP2013507415A5 (enExample)
JP2017533201A5 (enExample)
JP2019525948A5 (enExample)
JP2015505564A5 (enExample)
JP2016525097A5 (enExample)
JP2017222722A5 (enExample)
RU2017114352A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
RU2016132762A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
JP2014533272A5 (enExample)
JP2013533287A5 (enExample)
JP2016512817A5 (enExample)
JP2017503014A5 (enExample)
JP2018090566A5 (enExample)